Abstract:R ed blood cells (RBCs) are nature’s long-circulating delivery vehicles. They possess various remarkable properties and continue to inspire the design and engineering of man-made delivery systems. Inherently suited for intravascular delivery, RBCs are intrinsically biocompatible, biodegradable, and nonimmunogenic. They form natural compartments capable of protecting encapsulated cargos, and this allows them to circulate in the bloodstream for a long period of time (up to 120 days). In addition, their semipermeable membrane affords sustained release to smallmolecule drugs, yet they are ideal for retaining large proteins while providing them access to the substrates. Delivery vehicles possessing one or several of these properties have long been desired for efficacious therapeutics. A long-sought strategy for RBC-mimicking delivery vehicles is to load natural RBCs with therapeutic agents without compromising the structural integrity and biological functions of the RBCs. Various loading techniques, including automated loading devices, have been developed to enable the encapsulation of payloads with molecular weights of over 180 kDa into RBCs with maintenance of the carriers’ biological competence. In addition to the interior of RBCs, their exterior surface has also been coupled with therapeutic molecules, either covalently or physically, for various delivery applications. These RBC-based delivery vehicles, namely carrier RBCs, have been developed for the delivery of numerous therapeutic agents, including proteins, nucleic acids, and small-molecule drugs. Several of them have entered clinical tests to treat various diseases, including cancers and enzyme deficiencies. Meanwhile, advances in molecular biology have provided unprecedented understanding of the connections between the physicochemical characteristics of RBCs and their biological functions. This understanding, in turn, has inspired researchers to model drug carriers after RBCs. Designs that mimic the physicochemical characteristics and biological functions of RBCs, particularly those that enable their passage through narrow constrictions while maintaining a long in vivo survival, have been integrated into the engineering of drug carriers and have resulted in novel delivery systems with improved drug tolerability, circulation lifetime, and efficacy. Recently, the pursuit of RBC-mimicking nanoparticles led us to develop an intriguing approach for functionalizing synthetic nanoparticles with natural RBC membranes. In this approach, we first collected intact cellular membranes and then coated them onto polymeric nanoparticle cores, such as those made from poly(lactic-co-glycolic acid) (PLGA); this resulted in red-blood-cell-membrane–coated nanoparticles (RBC-NPs; Figure 1). Our aim was to fabricate cellmimicking nanoparticles through a top-down approach that bypassed the labor-intensive processes of protein identification, purification, and conjugation. The natural membranes also provide a bilayered medium for transmembrane protein anchorage while preventing common chemical modifications that could compromise the integrity and functionalities of these proteins. The independent preparation of cellular membranes and particle cores before coating offers a new level of engineering flexibility toward highly functional biomimetic nanoparticles. Since their initial development, RBC-NPs have provided an unprecedented capability for harnessing the natural functionalities of native cells that would otherwise be difficult to replicate. They have since inspired us to develop novel nanotherapeutics for better disease intervention. In this Perspective, we review our recent progress in developing RBC-NPs for three distinct biomedical applications: long-circulating nanocarriers for drug delivery, biomimetic nanosponges for detoxification, and nanotoxoids for safe and effective toxin vaccination.

Engineering Platelet-Mimicking Drug Delivery Vehicles

Engineering Unactivated Platelets for Targeted Drug Delivery

Platelets and Their Biomimetics for Regenerative Medicine and Cancer Therapies

Platelet-derived drug delivery systems: Pioneering treatment for cancer, cardiovascular diseases, infectious diseases, and beyond

Platelets and platelet extracellular vesicles in drug delivery therapy: A review of the current status and future prospects

Recent advances in platelet engineering for anti-cancer therapies

Engineered Platelets: Advocates for Tumor Immunotherapy

Platelet-derived biomaterials for targeted drug delivery and tissue repair

From bench to bedside: Platelet biomimetic nanoparticles as a promising carriers for personalized drug delivery

Engineering red‐blood‐cell‐membrane–coated nanoparticles for broad biomedical applications

Advancement and Applications of Platelet-inspired Nanoparticles: A Paradigm for Cancer Targeting

Remote-Loaded Platelet Vesicles for Disease-Targeted Delivery of Therapeutics

Anticancer Platelet-Mimicking Nanovehicles.

Platelet‐inspired nanomedicine in hemostasis thrombosis and thromboinflammation

Engineered Platelets for Cancer Therapy

Engineered platelets-based drug delivery platform for targeted thrombolysis

Engineering supramolecular peptide nanofibers for in vivo platelet-hitchhiking beyond ligand-receptor recognition

Platelet‐Drug Conjugates Engineered via One‐step Fusion Approach for Metastatic and Postoperative Cancer Treatment

A Platelet Intelligent Vehicle with Navigation for Cancer Photothermal-Chemotherapy

Expanding applications of allogeneic platelets, platelet lysates, and platelet extracellular vesicles in cell therapy, regenerative medicine, and targeted drug delivery

Engineered platelets as targeted protein degraders and application to breast cancer models